Ryan Hartmaier
Executive Director, Multimodal & Minimally Invasive Biomarkers, Oncology Research & Development AstraZeneca
Ryan Hartmaier is Executive Director, Multimodal & Minimally Invasive Biomarkers, Oncology R&D at AstraZeneca, a role held since July 2026. He has been at AstraZeneca since 2018, most recently as Senior Director, Translational Medicine. Previously, he was a Senior Scientist at Foundation Medicine and a Research Instructor at the University of Pittsburgh. He holds a PhD in Translational Biology & Molecular Medicine from Baylor College of Medicine.
Seminars
Thursday 18th March 2027
Building on SERENA-6: Advancing the Next Generation of ctDNA-Guided Clinical Programs
8:30 am
- Exploring where ctDNA is already informing clinical decision making today, using SERENA-6 as a leading example of acting on molecular resistance before imaging progression
- Building from established resistance monitoring toward longitudinal ctDNA strategies that can identify molecular progression ahead of imaging and enable earlier clinical decisions
- Looking ahead to emerging approaches such as functional liquid biopsy and integration with imaging to shape the future of ctDNA-guided care
Friday 19th March 2027
Panel Discussion: Harnessing Multimodal Technologies to Improve Patient Profiling for Increased Accuracy in Diagnostics
9:30 am
- Integrating protein, methylation and fragmentomic signal to resolve cases that genomic profiling alone leaves ambiguous
- Determining which analyte combinations improve accuracy enough to justify the added cost and complexity
- Embedding multi-omic workflows into patient selection and diagnostic paradigms
